Across TCGA pan-cancer cohorts, TRAV26-1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAV26-1 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher TRAV26-1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV26-1 expression acts as an unfavorable survival marker.

PRAD, LUAD, and SKCM are the cancer types where TRAV26-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.307	0.834	.007	6	view →
SKCM	DFS	Median	III,IV	0.050	0.648	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRAV26-1 tumor-vs-normal RNA expression · all TRAV26-1 data types